Arthiritis Rheum 48:1109–1116Ĭhang YJ, Spiera H (1999) Renal transplantation in scleroderma. (2003) Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. ![]() Br J Rheumatol 37:15–20īurastero SE, Galbiati S, Vassallo A, Sabbadini MG, Bellone M, Marchionni L et al. Br J Dermatol 135:302–304īunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA Polymerases and other autoantibody specificities in systemic sclerosis. Clin Rheumatol 15:148–153īottomley WW, Goodfield MJ, Sheehan-Dare RA (1996) Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Arthritis Rheum 42:299–305īlockmans D, Beyens G, Verhaege R (1996) Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Arthritis Res Ther 11(2):220īlack CM, Silman SJ, Herrick AI (1998) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double blind, placebo-controlled trial. Hypoxia in the pathogenesis of systemic sclerosis. (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. Ann Int Med 132:425–434īaroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al. N Engl J Med 338:1186–1191īadesch D, Tapson VF, McGoon MD (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Baillieres Best Pract Res Clin Rheumatol 14:125–137Īrtlett CM, Smith CB, Jimenez SA (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. This process is experimental and the keywords may be updated as the learning algorithm improves.Īlarcon GS (2000) Unclassified or undifferentiated connective tissue disease. These keywords were added by machine and not by the authors. Therefore, future treatments should be designed to specifically target distinct pathogenetic pathways in SSc. in pulmonary fibrosis or kidney failure). The associated side effects and lack of efficacy in certain subgroups of organ involvement indicate however, that the available treatment options are still unsatisfactory (e.g. The introduction of drugs that treat organ complications has changed markedly, the mortality and life quality of subgroups of SSc. ![]() Survival has markedly improved over the past two decades, with the 10-year survival rate approaching 80%, although to date with the exception of cyclophosphamide there is no effective disease-modifying treatment of SSc. Despite intense research efforts and major advances in the understanding of particular aspects of the disease process, the etiology of SSc is still unknown and the pathogenesis only partly understood.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |